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Barbora Servusova-Vanaskova,*a Ondrej Jandourek,a Pavla Paterova,a
Jana Kordulakova,b Magdalena Plevakova,a Vladimir Kubicek,a Radim Kucera,a
Vladimir Garaj,c Lieve Naesens,d Jiri Kunes,a Martin Dolezala and Jan Zitko*a
A series of alkylamino derivatives of N-benzylpyrazine-2-carboxamide was designed, synthesized and
assayed in vitro for their antimycobacterial, antibacterial, antifungal as well as antiviral activities. Final
structures were prepared from 6-chloro (1), 5-chloro (2) or 3-chloro (3) derivatives of N-benzylpyrazine-2-
carboxamide by nucleophilic substitution of chlorine with n-alkylamines in the range from butylamine to
octylamine (labelled a–e). Series 1a–e and 2a–e exerted higher activity against Mycobacterium tuberculosis
H37Rv compared to the corresponding pattern compounds and the reference compound pyrazinamide.
The most active derivatives reached an activity MIC = 4.6–10 μM (M. tbc H37Rv). More importantly, activity
was also observed against other tested mycobacterial strains (including drug-resistant strains). Substitution
of 3-chlorine was disadvantageous and led to completely inactive compounds 3a–e. Some compounds
showed activity against Gram-positive bacterial strains (including MRSA) or influenza virus, but no antifungal
activity was observed.Introduction
Even in the 21st century, tuberculosis (TB) still remains a seri-
ous and global health threat. The absolute number of TB
cases per year has been slightly decreasing since the begin-
ning of this millennium,1,2 nevertheless in 2013 about 9
million new cases of TB were reported and associated with
1.5 million deaths.3 The alarming increase of drug-resistant
strains underlines the need for new antituberculosis drugs.
One strategy to design potential new drugs is by
structural-modification of known and therapeutically used
drugs. Pyrazinamide (PZA) is a first-line antituberculotic
drug4 with multiple mechanisms of action. It acts under its
parent form or as a prodrug metabolized to pyrazinoic acid(POA).5–8 One of the confirmed mechanisms of action for
both PZA and POA is the inhibition of mycobacterial fatty
acid synthase I (FAS I), which leads to depletion of mycolic
acid-essential components of the mycobacterial cell wall.9
Due to its simple structure, the PZA scaffold is, in theory,
amenable to many diverse structural modifications.
Recently we reported that the antimycobacterial activity is
enhanced by n-alkylamino substitution of the pyrazine.10–13
As Zitko et al. stated, this type of substitution also led to less
toxic compounds compared to pattern chloropyrazine deriva-
tives.13 To confirm this hypothesis, a series of 6-alkylamino-
N-benzylpyrazine-2-carboxamides (1a–e) and 5-alkylamino-N-
benzylpyrazine-2-carboxamides (2a–e) were designed and syn-
thesized from their respective chloro-N-benzylpyrazine-2-carb-
oxamides (1, 2),14 which in our previous study exerted moder-
ate antimycobacterial activity (MIC = 50–100 μM) against
Mycobacterium tuberculosis H37Rv.14 To fully understand the
relationship between the position of the alkylamino chain
and antimycobacterial activity, a series of 3-alkylamino-N-
benzylpyrazine-2-carboxamides (3a–e) was prepared as well.
All compounds were evaluated for activity against four
standard mycobacterial strains and seven drug-resistant
strains of Mycobacterium tuberculosis. Additionally, their anti-
bacterial, antifungal and antiviral activities were determined.
Triclosan (TCL) and its derivatives are known inhibitors of
mycobacterial enoyl-ACP-reductase (InhA).15–17 InhA belongs
to the complex of fatty acid synthase II (FAS II) and is one ofun., 2015, 6, 1311–1317 | 1311
Scheme 1 Synthesis of pattern compound 1 and formation of side-
product 1′. Reaction proceeded under mild conditions – RT, 4 h. Side-
product originated in the ratio 1 : 5 by substitution of chlorine on the
pyrazine core with benzylamine.
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View Article Onlinethe crucial enzymes involved in the biosynthesis of mycolic
acids (modification of fatty acids produced by FAS I).18,19
With respect to the alkylamino derivatives presented in this
letter, it is very interesting that the 5-alkyl diphenyl ethers
(Fig. 1) with a C4 to C8 alkyl chain possessed significantly
lower IC50 values in the InhA in vitro enzyme inhibition
assay. Their inhibitory activity increased with growing alkyl
chain and 5-octyl-2-phenoxyphenol possessed an IC50 of 5
nM, which is a major improvement over TCL (IC50 = 1000
nM).20 The structural similarity between the 5-alkyl diphenyl
ethers (as derivatives of TCL) and the 5-alkylamino-N-
benzylpyrazine-2-carboxamides (2a–e) presented in this arti-
cle raised the question whether our compounds could pos-
sess the same mechanism of action as TCL and its alkyl
derivatives, i.e. based on inhibition of InhA. To test this
hypothesis, we performed molecular docking of selected com-
pounds into mycobacterial InhA.
Results and discussion
Chemistry
The pattern compounds 1 and 2 were described previously,14
nevertheless the synthesis of compound 1 was modified. To
increase the reaction yield, Schotten–Bauman conditions
were applied. Excess of benzylamine was dissolved in water
and added portionwise to 6-chloropyrazine-2-carbonyl chlo-
ride in dichloromethane. The reaction mixture was stirred
for about 4 hours at RT. A portion of originating N-benzyl-6-
chloropyrazine-2-carboxamide (1) reacted further with excess
of benzylamine and yielded N-benzyl-6-benzylaminopyrazine-
2-carboxamide (1′, Scheme 1) as an unintended side-product.
Its structure was confirmed by NMR and MS analysis. Forma-
tion of this type of side-product was also observed during the
synthesis of pattern compound 3, for which the synthetic pro-
cedure is thoroughly explained in the ESI.†
The syntheses of compounds 1a–e and 2a–e were performed
via a aminodehalogenation reaction, where corresponding pat-
tern compound 1 or 2 was treated with 5 equivalents of the
respective amine using triethylamine as a base (Scheme 2A).
The reaction mixture was refluxed in a small amount of ethanol
up to 8 hours as indicated by TLC (silica, hexane–EtOAc 2 : 1).
The synthesis of final compounds 3a–e was accelerated by
microwave irradiation. Microwave conditions were determined
experimentally in previous research,21 (Scheme 2B).
The crude products were absorbed on silica gel and purified
by flash-chromatography (gradient elution, hexane–EtOAc). To
remove residual non-aromatic amine, derivatives 1a–2e were1312 | Med. Chem. Commun., 2015, 6, 1311–1317
Fig. 1 Structures of triclosan (TCL) and its 5-alkyl derivatives with
enoyl-ACP-reductase inhibitory activity.recrystallized from ethanol. Compounds 1a–e and 2a–e were iso-
lated as white solids, compounds 3a–e as yellow liquids. The
analytical data, which were fully consistent with the proposed
structures, are included in the ESI.† The yields (chromatographi-
cally pure product) ranged from 37% to 80%.Antimycobacterial activity
All the prepared compounds (including compounds 1, 2 and
3) as well as the clinically used standards PZA and isoniazid
(INH) were evaluated using the microplate alamar blue assay
(MABA)22 for activity against Mycobacterium tuberculosis
H37Rv (Mtb), M. kansasii and two strains of M. avium. The
results were expressed as minimal inhibitory concentration
(MIC) in μg mL−1 or μM (data in parentheses), Table 1. Both
tested strains of Mycobacterium avium were completely resis-
tant to the tested compounds (MIC >100 μg mL−1). Compar-
ing the results in μM, alkylamino derivatives 1a–e and 2a–e
showed higher activity against Mtb H37Rv than the corre-
sponding pattern compounds 1 (MIC = 50 μM) and 2 (MIC =
100 μM). For the most active derivatives 1d, 1e and 2c-e (MIC
= 4.6–10 μM), the activity was up to 20-times better compared
to the clinically used drug PZA (MIC = 102 μM).
More importantly, compounds 1a–e derived from
N-benzyl-6-chloropyrazine-2-carboxamide (1) exhibited activity
against Mycobacterium kansasii (naturally resistant to PZA,This journal is © The Royal Society of Chemistry 2015
Scheme 2 Syntheses of target structures. (A): Pattern compound 1 or
2 refluxed in EtOH with corresponding n-alkylamine up to 8 h,
triethylamine (TEA) was used as a base (conditions a). (B): Microwave
assisted syntheses of final compounds 3a–e. Conditions b: 140 °C, 30
minutes, 120 W, MeOH, pyridine.
Table 1 Summary of prepared compounds. In vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv (Mtb) and Mycobacterium
kansasii, MIC in μg mL−1 or μM (data in parentheses). Cytotoxicity provided on different types of cells, expressed as CC50 or MCC in μM. Anti-influenza
virus activity and cytotoxicity provided on MDCK cells, values in μM
No. Log k R
MIC μg mL−1 (μM) Cytotoxicity (μM) Antiviral activity (μM)
Mtb
H37Rv
M.
kansasii
CRFKa
CC50
HELb
MCC
HeLac
MCC
Verod
MCC
MDCKe
cytotoxicity
Antiviral EC50
f
Influenza A/H1N1
ĲA/PR/8)
CC50 MCC Visual CPE score MTS
1 0.200 — 12.5 (50) 100 (404) n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
1′ 0.483 6-Benzyl 50 (157) >100 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
1a 0.549 6-C4H9 12.5 (44) 50 (176) >100 >100 >100 100 66 100 >100 >100
1b 0.768 6-C5H11 12.5 (42) 25 (84) >100 >100 >100 >100 33 20 >100 >100
1c 0.986 6-C6H13 6.25 (20) 12.5 (40) >100 >100 >100 100 9.5 20 >100 >100
1d 1.207 6-C7H15 3.13 (10) 12.5 (38) >100 >100 >100 >100 2.4 4.0 >100 >100
1e 1.431 6-C8H17 3.13 (9.2) 6.25 (18) >100 >100 >100 >100 1.3 4.0 >100 >100
2 0.186 — 25 (100) 100 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
2a 0.424 5-C4H9 25 (88) >100 >100 >100 >100 >100 57 100 >100 >100
2b 0.638 5-C5H11 6.25 (21) >100 >100 >100 >100 >100 >100 >100 37 3.3
2c 0.859 5-C6H13 3.13 (10) >100 >100 >100 >100 ≥100 >100 >100 52 62
2d 1.089 5-C7H15 3.13 (10) >100 >100 >100 >100 ≥100 >100 >100 21 47
2e 1.312 5-C8H17 1.56 (4.6) >100 28 100 100 20 62 ≥20 1.1 >100
3 n.d. — 12.5 (50) 100 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
3′ 1.040 3-Benzyl >100 >100 >100 >100 >100 >100 >100 20 >100 >100
3a 1.081 3-C4H9 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100
3b 1.321 3-C5H11 >100 >100 >100 ≥100 >100 >100 >100 ≥20 >100 >100
3c 1.564 3-C6H13 >100 >100 >100 100 >100 >100 >100 100 >100 >100
3d 1.809 3-C7H15 >100 >100 >100 100 >100 >100 >100 100 >100 >100
3e 2.054 3-C8H17 >100 >100 >100 >100 >100 >100 >100 100 >100 >100
PZA −0.687 12.5 (102) >100 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
INH −0.743 0.39 (2.8) 1.56 (11) n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Log k stated as average of n = 3, SD values were negligible, relatively ranging from 0.01 to 0.19%.a Crandell feline kidney cells. b Human
embryonic lung fibroblasts. c Human cervix epithelial cells. d African green monkey kidney cells. e Madin canine kidney cells. f EC50 –
concentration producing 50% inhibition of virus-induced cytopathic effect (CPE), as determined by visual scoring of the CPE or by measuring
the cell viability with colorimetric formazan-based MTS assay. n.d. not done. MCC – compound concentration producing minimal changes in
cell morphology estimated by the MTS cell viability assay.
Chart 1 Correlation between antimycobacterial activity and
lipophilicity expressed as log k.
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View Article OnlineMIC > 100 μg mL−1), while 5-alkylamino isomers (2a–e) as
well as 3-alkylamino isomers (3a–e) were completely inactive
(MIC > 100 μg mL−1). Actually, compounds 3a–e derived from
N-benzyl-3-chloropyrazine-2-carboxamide (3) did not exhibit
activity against any tested mycobacterial strain.
In concordance with previously published studies on
alkylamino derivatives of PZA,10–13 the activity of
6-alkylamino (1a–e) and 5-alkylamino (2a–e) isomers
depended on the length of the alkyl chain and culminated in
compounds with hexyl- to octylamino substitution. Chart 1
shows the correlation between lipophilicity (expressed as log
k) and antimycobacterial activity against Mtb (for compounds
1a–e and 2a–e) and M. kansasii (for compounds 1a–e).
All alkylamino derivatives 1a–e, 2a–e and 3a–e were evalu-
ated for activity against resistant strains of Mycobacterium
tuberculosis. As shown in Table 2, the 6- and 5-alkylamino
derivatives exhibited activity, which was again dependent on
the length of the alkyl chain, i.e. compounds with a C6–C8
chain (labelled c–e) exhibited the highest activity. Examples
of correlation between lipophilicity and activity against resis-
tant strains are included in the ESI.† The 5-isomers (2a–e)
showed higher activity compared to their respective 6-isomersThis journal is © The Royal Society of Chemistry 2015(1a–e). Poor activity was observed for compound 3a ĲN-ben-
zyl-3-butylpyrazine-2-carboxamide), while the rest of the
3-alkylamino derivatives were inactive (MIC ≥ 1000 μM).
Simoes et al.23 reported a series of amides of pyrazinoic
acid, which exhibited very slow hydrolysis in the plasma, ratMed. Chem. Commun., 2015, 6, 1311–1317 | 1313
Table 2 Antimycobacterial activity against drug-resistant strains, minimal inhibitory concentrations in μM
MIC (μM)
No. R
Mtb
7357/1998 Mtb 234/2005
Mtb
9449/2007
Mtb
8666/2010 Mtb Praha 1 Mtb Praha 4 Mtb Praha131
14 d 21 d 14 d 21 d 14 d 21 d 14 d 21 d 14 d 21 d 14 d 21 d 14 d 21 d
1a 6-C4H9 62.5 62.5 62.5 62.5 62.5 125 62.5 62.5 62.5 62.5 32 62.5 32 62.5
1b 6-C5H11 32 62.5 62.5 62.5 32 62.5 62.5 62.5 62.5 62.5 32 62.5 32 62.5
1c 6-C6H13 32 32 16 32 32 32 16 32 16 32 32 32 16 32
1d 6-C7H15 16 16 16 16 16 16 16 16 16 16 8 16 8 16
1e 6-C8H17 16 16 16 16 16 16 16 16 16 16 16 16 16 16
2a 5-C4H9 125 125 125 250 62.5 125 125 250 125 250 62.5 125 62.5 125
2b 5-C5H11 16 32 16 32 16 32 16 32 16 32 16 32 16 16
2c 5-C6H13 8 8 4 8 8 8 4 8 4 8 8 8 4 4
2d 5-C7H15 4 8 4 4 4 8 4 4 4 4 4 8 2 4
2e 5-C8H17 8 8 4 8 8 8 4 8 4 8 8 8 4 4
3a 3-C4H9 125 250 125 250 125 250 125 250 125 125 125 125 125 250
3b 3-C5H11 10
3 >103 103 >103 103 >103 103 >103 103 >103 103 >103 103 >103
3c 3-C6H13 10
3 >103 103 >103 103 103 103 >103 103 >103 103 >103 103 >103
3d 3-C7H15 10
3 103 103 >103 >103 >103 103 >103 103 >103 >103 >103 103 >103
3e 3-C8H17 >10
3 >103 >103 >103 >103 >103 >103 >103 >103 >103 >103 >103 >103 >103
INH 16 32 16 16 16 16 16 32 16 16 16 16 16 16
MDR-TB strains: 234/2005 and 7357/1998 both resistant to INH, rifampicin (RIF), rifabutin, streptomycin, ethambutol and ofloxacin; Praha 1
resistant to INH, RIF, rifabutin, streptomycin, ethambutol and clofazimine; 8666/2010 resistant to INH, RIF, rifabutin; 9449/2007 and Praha 4
both resistant to INH, RIF, rifabutin, ethambutol and streptomycin. XDR-TB strain: Praha 131 resistant to INH, RIF, rifabutin, streptomycin,
ethambutol, ofloxacin, gentamicin and amikacin.
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View Article Onlineliver homogenate and were even stable in M. smegmatis
homogenate. These derivatives failed in antimycobacterial
testing and Simoes et al.23 assumed that the lack of activity is
caused by insufficient rate of hydrolysis to POA. Our deriva-
tives are sterically more demanding (large substituent on the
carboxamide moiety) than the simple amides tested by
Simoes et al.,23 therefore their stability (resistance to ami-
dases) is expected to be even higher. According to the
results23 and previously published studies,12,24 we do not
expect that the presented derivatives are hydrolyzed to their
corresponding pyrazinecarboxylic acids.
Antibacterial and antifungal activities
The studied compounds were evaluated against eight bacte-
rial and eight fungal strains (see the ESI† for the complete
list of tested strains). All fungal strains as well as Gram-
negative strains were completely insensitive to the tested
compounds (MIC > 500 μM). Compounds 1a–e exhibited
moderate or weak activity against Gram-positive strains
including methicillin-resistant Staphylococcus aureus. Nota-
bly, compound 1e ĲN-benzyl-6-octylpyrazine-2-carboxamide)
displayed activity against S. aureus (MIC = 3.9 μM) compara-
ble to the reference compounds (see the ESI†).
Toxicity assay
In vitro cytotoxicity25–27 assays on several cell lines were
performed for compounds 1a–e, 2a–e and 3a–e. The results
(Table 1) were expressed as the concentration causing mini-
mal changes in cell morphology (MCC) or as 50% cytotoxic
concentration (CC50) – a concentration reducing cell viability1314 | Med. Chem. Commun., 2015, 6, 1311–1317by 50% as assessed by a colorimetric formazan assay. Except
for compound 2e, the tested compounds were not cytotoxic
in CRFK, HEL, HeLa and Vero cell lines at the highest con-
centration tested, i.e. 100 μM.Antiviral activity
In addition, we determined whether any of the studied com-
pounds has potential activity against diverse DNA and RNA
viruses. The virus panel (see the ESI† for the full list)
included pathogens of medical importance such as herpesvi-
ruses, HIV and influenza virus. Most compounds did not pro-
duce any visible antiviral activity. The notable exception was
series 2b–e which was moderately active against the influenza
virus, with 2e being the most potent one (Table 1). The latter
compound also inhibited the replication of respiratory syncy-
tial virus (data not shown) with an antiviral EC50 value of 8.9
μM. The basis for the antiviral effect of 2b–e remains to be
identified.Docking
To perform the docking studies, we selected the derivatives
with the highest antimycobacterial activity in the whole cell
assay, i.e. hexylamino to octylamino derivatives (1c-e, 2c–e).
We included their corresponding 3-alkylamino isomers
(3c–3e) to test the influence of the position of the alkylamino
chain on the docking results. Out of the large number of crys-
tal structures of InhA available from the Protein Data Bank,
we chose PDB entry: 2X23. This structure is a closed form of
the enzyme co-crystalized with inhibitor PT70, which is aThis journal is © The Royal Society of Chemistry 2015
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View Article Onlineslow and tight-binding inhibitor with an alkyl diphenyl ether
structure.28
To verify the docking procedure, the co-crystallized ligand
(PT70) from the PDB structure was removed and redocked
using Glide XP mode docking protocol with flexible sampling
of ligand. The RMSD of the core atoms of the ligand (omit-
ting the atoms of the flexible alkyl chain) was approx. 0.26 Å.
According to the results of the molecular docking (Fig. 2A),
the 6-alkylamino-N-benzylpyrazine-2-carboxamides (1c–e) and
5-alkylamino-N-benzylpyrazine-2-carboxamides (2c–e) may
exert interactions typical for TCL-based inhibitors of myco-
bacterial enoyl-ACP-reductase InhA.20,28 The carboxamide
oxygen of the presented compounds plays the same role as
the phenolic oxygen of TCL, i.e. to act as an H-bond acceptor,
forming interactions with the –OH group of Tyr158 and the
2′-hydroxyl of the ribose of NAD+. The pyrazine core of the
title compounds is oriented similarly to the phenol aromatic
ring of the TCL derivatives (the so called A-ring) and shows a
π–π stacking interactions with the nicotinamide core of
NAD+, and π–π edge-to-face interactions with Phe149. The
benzyl core of the discussed derivatives occupies the same
hydrophobic cavity as the B-ring of the TCL derivatives. The
planes of the (hetero)aromatic rings of the title compounds
are almost identical to the corresponding planes of PT70
(Fig. 2B). The alkylamino chain is placed in the tunnel lead-
ing to the enzyme's surface, in the same manner as the alkyl
chain of PT70 and similar TCL derivatives. This hydrophobic
entry tunnel hosts the lipophilic chain of the mycolic acid
intermediate, which is the substrate of the InhA enzyme. The
docking scores of the presented compounds (see the ESI†)
were close to the score of the co-crystallized ligand PT70 (the
best score was predicted for 1e, XP GScore = −9.705; the XP
GScore of PT70 was −10.543).
On the contrary, the 3-alkylamino derivatives 3c–e were
not able to orient inside the cavity of the active site in a man-
ner similar to PT70, and had low docking scores (XP GScore
from −3.692 for 3c to −6.175 for 3e). Apparently, the presence
of two large substituents (benzyl and alkylamino chain) on
neighbouring atoms C2 and C3 of the pyrazine core leads to
a molecular shape that is not compatible with the cavity.
To summarize, compounds 1c–e and 2c–e showed all
important ligand–enzyme interactions of triclosan andThis journal is © The Royal Society of Chemistry 2015
Fig. 2 (A) Compounds 1c–e (orange carbons) and 2c–e (green carbons) do
PDB: 2X23). (B) Predicted poses of 1e (orange carbons) and 2e (green car
and sticks).therefore could be potential inhibitors of InhA. This hypothe-
sis was tested via analysis of mycolic acid production in the
strain of M. tuberculosis H37Ra treated with compounds 1d
and 2e as described in the following paragraph. These deriva-
tives were chosen according to their MIC values for M. tuber-
culosis H37Rv and selectivity to the mycobacterial strains.
The XP GScore was not taken as the main criterion for selec-
tion, having in mind that derivatives with longer alkyl chain
will have a higher score caused mainly by non-specific hydro-
phobic interactions with the enzyme. Compound 1e (reaching
the highest XP GScore) was excluded from the screening due
to low selectivity (antibacterial and antiviral activities).Effect on mycolic acid production
The effect of compounds 1d and 2e on mycolic acid synthesis
was evaluated by metabolic labelling of Mycobacterium tuber-
culosis H37Ra with 14C acetate. Derivatized radiolabeled fatty/
mycolic acids were separated by thin layer chromatography
(TLC) and visualized by autoradiography. Isoniazid (INH)-
inhibiting mycobacterial enoyl-ACP-reductase (InhA)29 was
used as a control drug. As expected, the treatment of Mtb
with INH led to the inhibition of the synthesis of all types of
mycolic acids and the production of short chain fatty acids
was not affected. The compounds 1d and 2e did not affect
mycolic acid synthesis (Fig. 3).Lipophilicity
Lipophilicity parameter C logP was calculated by CS
ChemBioDraw Ultra version 14.0. (CambridgeSoft, Cam-
bridge, MA, USA). Additionally, the lipophilicity was mea-
sured experimentally by RP-HPLC and expressed as log k
derived from the retention times of individual compounds.
Correlation between the calculated C log P and the experi-
mentally determined log k values showed linearity inside the
series of positional isomers. As discussed in the ESI,† the
C log P algorithm did not correctly reflect the influence of
the position of the alkylamino substituent on a compound's
lipophilicity. Therefore logk is more useful for interseries com-
parisons and is used as the main lipophilicity parameter in
this manuscript.Med. Chem. Commun., 2015, 6, 1311–1317 | 1315
cked into the active site of mycobacterial enoyl-ACP-reductase (InhA,
bons) in comparison with the co-crystallized inhibitor PT70 (grey balls
Fig. 3 Analysis of the effects of 1d and 2e on mycolic acid synthesis.
The autoradiograph of TLC with separated fatty acid methyl esters
(FAME) and mycolic acid methyl esters (MAME) obtained from ĳ1,2-
14C]-acetate-labelled Mtb H37Ra strain treated with 1d, 2e or INH in
final concentration of 5.0 μg mL−1. Line C – untreated control.
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View Article OnlineConclusions
To conclude, substitution of 6-chlorine or 5-chlorine with
n-alkylamino substituent yielded derivatives with comparable
or increased activity against Mycobacterium tuberculosis
H37Rv compared to the corresponding pattern compounds 1
and 2. No significant differences between 6-alkylamino (1a–e)
and 5-alkylamino (2a–e) isomers were observed. Generally,
activity increased with prolongation of the alkyl chain (corre-
sponding to the increase in lipophilicity) and culminated in
compounds with heptylamino (1d, 2d) and octylamino (1e,
2e) substitution. The series of 6-alkylamino-N-benzylpyrazine-
2-carboxamides (1a–e) also exerted activity against Mycobacte-
rium kansasii, which is naturally resistant to pyrazinamide.
The 6-alkylamino and 5-alkylamino isomers also showed
activity against drug-resistant strains of Mycobacterium tuber-
culosis culminating in heptyl/octylamino derivatives, where
the 5-alkylamino isomers exhibited marginally higher activity
compared to the 6-isomers.
On the contrary to series 1 and 2, substitution of chlorine
with an alkylamino substituent in N-benzyl-3-chloropyrazine-
2-carboxamide (3, MIC = 12.5 μg mL−1 for Mtb), led to inac-
tive 3-alkylamino derivatives (3a–e).
In vitro activity of PZA is strongly dependent on pH and
decreases with the increase in pH. The MIC value for PZA
was in accordance with the literature.23,30,31
The studied compounds exhibited no antifungal activity and
mostly no significant antibacterial activity. The only exception
was compound 1e ĲN-benzyl-6-octylpyrazine-2-carboxamide),
showing activity against Staphylococcus aureus (MIC = 3.9 μM).
Side-products 1′ and 3′ occurring during the synthesis of
pattern compounds 1 and 3 were evaluated for their biologi-
cal activities and no significant activity was observed.
Based on the results of the in vitro cytotoxicity assays, we
assume that the presented derivatives are non-toxic.
Molecular docking of compounds 1c–e and 2c–e suggested
potential inhibition of mycobacterial enoyl-ACP-reductase. In1316 | Med. Chem. Commun., 2015, 6, 1311–1317view of these results, an in vitro study was performed. How-
ever, no effect on mycolic acid synthesis was observed for
selected compounds 1d and 2e.
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